Blood Screening Leads Revival of China’s National Blood Program

Blood Screening Leads Revival of China’s National Blood Program

Investment in screening diagnostics is pivotal in China’s effort to strengthen its scandal-bitten national blood program. Kalorama Information’s recently published Blood Testing Market in China provides IVD-relevant insights into both regional and national demand for blood screening products in China. Blood supply in China is insufficient today to meeting clinical demand in China, but increased donation is being encouraged as blood centers update screening standards and works to improve transfusion safety. Market opportunities for blood screening diagnostics in China relate primarily to blood center upgrading to nucleic acid testing (NAT) methods, expansion of screening capacity, and expansion of the blood supply system to underserved regional markets.

Primary research for the Kalorama Information report was conducted by the Beijing office of the Freedonia Group (part of MarketResearch.com) and consisted of interviews with national experts and managers of blood collection centers across China. The diversity of China’s provincial market was captured by interviews in the provinces of Shaanxi, Guangdong, Beijing, Henan, Yunnan and Heilongjiang. The interviews with blood centers and consultations with industry experts revealed a strong upswing in terms of donation volumes and voluntary participation for the national blood program. Five-year historical trends for program collection are auspicious for further growth in the blood screening market through 2020. Penetration of NAT was found to vary at different levels of the blood supply system between provincial, regional, and county blood centers.

The $275 million Chinese blood screening market contrasts to larger markets in the developed world in terms of growth; NAT penetration is complete in countries such as the United States where blood collection is actually declining. Growth in the Chinese blood screening market remains strong despite low public confidence in the national blood supply as a result of scandals, cultural aversion to blood donation, and restrictions on blood donation frequency aimed at preventing high-profile outbreaks of transfusion transmitted infections (TTIs). Improved recruitment of regular, low-risk blood donors and broader public participation in blood donations will be both a driver and product of restored public faith in the national blood program. Challenges in the Chinese market remain in the form of domestic IVD competitors successful in securing procurement orders managed individually by province.

The report Blood Testing Market in China offers specialized analysis into the state of blood screening standards in China across several representative provinces; the infrastructure and supply of the Chinese national blood program; major global and local competitors active in the market; and projects blood screening diagnostics markets in China to 2020.